Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport

被引:31
作者
Ji, Y [1 ]
Morris, ME [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Amherst, NY 14260 USA
关键词
breast cancer resistance protein; isothiocyanates; membrane transport;
D O I
10.1007/s11095-004-7679-1
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To investigate the effect of organic isothiocyanates (ITCs), dietary compounds with chemopreventive activity, on breast cancer resistance protein (BCRP)-mediated transport. Methods. The effect of 12 ITCs on the cellular accumulation of mitoxantrone (MX) was measured in both BCRP-overexpressing and BCRP-negative human breast cancer (MCF-7) and large cell lung carcinoma (NCI-H460) cells by flow cytometric analysis. The ITCs showing activity in MX accumulation were examined for their effect on MX cytotoxicity, and the intracellular accumulation of radiolabeled phenethyl isothiocyanate (PEITC) was measured in both BCRP-overexpressing and BCRP-negative NCI-H460 cells. Results. ITCs significantly increased MX accumulation and reversed its cytotoxicity in resistant cells, but had a small or no effect in sensitive cells. The effects of ITCs on MX accumulation and cytotoxicity were ITC-concentration dependent. Significant increases in MX accumulation were observed at ITC concentrations of 10 or 30 muM, and significant reversal of MX cytotoxicity was generally observed at ITC concentrations of 10 muM. Intracellular accumulation of radiolabeled PEITC in BCRP-overexpressing cells was significantly lower than that in BCRP-negative cells and was increased significantly by the BCRP inhibitor fumitremorgin C (FTC). Conclusions. Certain ITCs are BCRP inhibitors and PEITC and/or its cellular metabolite(s) may represent BCRP substrates, suggesting the potential for diet-drug interactions.
引用
收藏
页码:2261 / 2269
页数:9
相关论文
共 39 条
[21]  
Maliepaard M, 1999, CANCER RES, V59, P4559
[22]   Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells [J].
Nakatomi, K ;
Yoshikawa, M ;
Oka, M ;
Ikegami, Y ;
Hayasaka, S ;
Sano, K ;
Shiozawa, K ;
Kawabata, S ;
Soda, H ;
Ishikawa, T ;
Tanabe, S ;
Kohno, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (04) :827-832
[23]   Pheophorbide a is a specific probe for ABCG2 function and inhibition [J].
Robey, RW ;
Steadman, K ;
Polgar, O ;
Morisaki, K ;
Blayney, M ;
Mistry, P ;
Bates, SE .
CANCER RESEARCH, 2004, 64 (04) :1242-1246
[24]   A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2) [J].
Robey, RW ;
Honjo, Y ;
van de Laar, A ;
Miyake, K ;
Regis, JT ;
Litman, T ;
Bates, SE .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1512 (02) :171-182
[25]   Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity [J].
Robey, RW ;
Honjo, Y ;
Morisaki, K ;
Nadjem, TA ;
Runge, S ;
Risbood, M ;
Poruchynsky, MS ;
Bates, SE .
BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1971-1978
[26]   Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview [J].
Schinkel, AH ;
Jonker, JW .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (01) :3-29
[27]  
SCHURR E, 1989, CANCER RES, V49, P2729
[28]   NEW COLORIMETRIC CYTOTOXICITY ASSAY FOR ANTICANCER-DRUG SCREENING [J].
SKEHAN, P ;
STORENG, R ;
SCUDIERO, D ;
MONKS, A ;
MCMAHON, J ;
VISTICA, D ;
WARREN, JT ;
BOKESCH, H ;
KENNEY, S ;
BOYD, MR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (13) :1107-1112
[29]  
Smith G., 1985, Parasitology Today, V1, P76, DOI 10.1016/0169-4758(85)90047-X
[30]   BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia [J].
Steinbach, D ;
Sell, W ;
Voigt, A ;
Hermann, J ;
Zintl, F ;
Sauerbrey, A .
LEUKEMIA, 2002, 16 (08) :1443-1447